Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 9,169

Document Document Title
WO/2018/013774A1
Disclosed are compounds of Formula (I) to (VIII): (I) (II) (III) (IV) (V) (VI) (VII) (VIII); or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein R3 is a bicyclic heteroaryl group substituted...  
WO/2018/012508A1
Provided are: a novel aromatic compound which has properties of a semiconductor showing excellent carrier mobility; an organic semiconductor material and a composition for thin film formation use, each of which contains the compound; an ...  
WO/2018/013776A1
Disclosed are compounds of Formula (I) to (VIII): (I) (II) (III) (IV) (V) (VI) (VII) (VIII) or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein R3 is a tricyclic heteroaryl group substituted...  
WO/2018/007479A1
The invention relates to novel organic semiconducting compounds containing a polycyclic unit, to methods for their preparation and educts or intermediates used therein, to compositions, polymer blends and formulations containing them, to...  
WO/2018/006530A1
A chloro-benzothiadiazole-containing conjugated polymer, a preparation method therefor and an organic solar cell device. The chloro-benzothiadiazole-containing conjugated polymer is represented by structural formula (1), wherein Ar is on...  
WO/2018/009938A1
Disclosed are imidazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure [Formula should be inserted here] and pharmaceutically acceptable salts, prodrugs and...  
WO/2018/001952A1
The present invention provides novel compounds having general formula (I), wherein R1 to R4, A, W, Q and Y are as described herein, compositions including the compounds and methods of using the compounds.  
WO/2018/003962A1
2- (Piperidin-1-yl) pyrimidin-4 (3H) -ones characterized by having a 1,8-diazaspiro [4.5] deca-3-ene, 1-oxa-8-azaspiro [4.5] deca-3-ene, 2,8-diazaspiro [4.5] deca-3-ene, 2-oxa-8-azaspiro [4.5] deca-3-ene, 2,9-diazaspiro [5.5] undeca-3-en...  
WO/2018/001330A1
Provided are porphyrin small molecules substitutes designed and synthesized for bulk hetero junction (BHJ) organic solar cells (OSOs). Provided are synthesized materials with strong and ordered self-assembly property, leading to form bic...  
WO/2018/005336A1
The present invention provides compounds of Formula (I): wherein the substituents are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or e...  
WO/2018/001944A1
The present invention provides novel compounds having the general formula: wherein R1, R2, A and X are as described herein, compositions including the compounds and methods of using the compounds.  
WO/2017/220670A1
The subject of the present invention is symmetric or dissymmetric azomethine direct dyes comprising at least one pyrazolopyridine unit of formula (I), a composition comprising said dyes, a process for treating keratin fibers using said d...  
WO/2017/219800A1
Selective mTOR inhibitors of formulas (I)-(III), processes for their preparation, pharmaceutical compositions containing them, and their use in the treatment of diseases and disorders, arising from abnormal cell growth, functions, or beh...  
WO/2017/223231A1
Disclosed herein is the use of a specific compound e.g. (S)-8-(benzhydryl )-6-isopropyl-3,5-dioxo- 5, 6,7,8,-tetrahydro-3H-pyrazino-[1,2-b]pyridazin-yl-isobutyrat e (RegNo 1674397-77-3) for use in a method of treating an influenza infect...  
WO/2017/216706A1
The present invention relates to compounds of formula I: in which Y1, Y2, R1, R2 and R3 are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation...  
WO/2017/216791A1
Provided herein is a conjugate comprising two residues of structurally and/or mechanistically different anticancer bioactive agents, coupled to one another by a biocleavable linking moiety, as well as methods of treating cancer using the...  
WO/2017/215600A1
Provided are a substituted tricyclic herteocyclic compound of formula I or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt, ester or a prodrug thereof, a pharmaceutical compo...  
WO/2017/212385A1
Compounds of the general formula : processes for the preparation of these compounds, compositions containing these compounds, and the compounds for use in treating cancer.  
WO/2017/214269A1
Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, incl...  
WO/2017/213210A1
The present invention relates to a compound potentially useful as a prophylactic or therapeutic drug for cancer.  
WO/2017/210966A1
An organic photoelectric material and an organic electroluminescent device comprising the organic photoelectric material. The organic photoelectric material is represented by formula I. R1 and R2 are independently selected from a hydroge...  
WO/2017/205425A1
Described herein are molecules for use in organic light emitting diodes comprising at least one moiety A, at least one moiety D, and at least one moiety B.  
WO/2017/202390A1
Provided in the present invention is a heterocyclic compound serving as an FGFR4 (fibroblast growth factor receptor 4) inhibitor. Specifically, provided in the present invention is the compound shown in formula (I), including isomers (en...  
WO/2017/205538A1
The present invention relates to a compound formula (I): and to salts thereof, wherein R1, R2X, and Y have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. A...  
WO/2017/203459A1
The present application relate to a process for preparation of 4-Methylene tetrahydrofuran compound of formula II, which is useful as an intermediate for the preparation of halichondrin B analogues such as Eribulin.  
WO/2017/200068A1
Provided is a compound useful as an AMPK activator. A compound represented by formula (1) (wherein R1 represents a hydrogen atom or a substituted or unsubstituted alkyl group; R2 represents a substituted or unsubstituted alkyl group, a s...  
WO/2017/200857A1
Provided are methods for treating or preventing a fibrotic disease selected from systemic sclerosis, cystic fibrosis, non-alcoholic steatohepatitis, Peyronie's disease, or interstitial lung disease; the method comprising administering a ...  
WO/2017/198122A1
The present invention belongs to the field of chemical medicine, and in particular, relates to an anti-influenza small molecule compound and a preparation method and use thereof. The technical problems to be solved by the invention are t...  
WO/2017/196985A1
Provided herein are palladium (Pd) catalysts with improved performance in biological environments. In particular, formulations, methods of preparations, and storage conditions are provided that provide improved performance of Pd catalyst...  
WO/2017/194459A1
The present application relates to new substituted 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridine-3(2H)-ones and 2,5,6,7-tetrahydro-3H-pyrrolo[2,1-c][1,2,4]triazol-3-ones, to methods for the synthesis thereof, the use thereof alone or ...  
WO/2017/186668A1
The present invention relates to a process for the preparation of 2-pyrazolo[1,5-a]pyrazin-2-ylpyrido[1,2-a]pyrimidin-4-one derivatives useful as pharmaceutically active compounds.  
WO/2017/188287A1
The present invention relates to a substituted purine derivative represented by formula (1), which exhibits a strong TLR7 inhibitory effect and is useful for treating autoimmune diseases, etc., or a pharmaceutically acceptable salt there...  
WO/2017/188288A1
Provided is a compound useful as an AMPK activator. A compound represented by formula (I) or a pharmaceutically acceptable salt thereof. [In formula (I): L represents -NR1-, =N-, -O-, -S-, -SO2-, -CR2R3- or =CR2-; the broken line represe...  
WO/2017/188374A1
Provided is a compound, or a salt thereof, represented by formula (I) [in the formula, each symbol is as defined in the description of the present invention].  
WO/2017/182418A1
The present invention relates to compounds, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and...  
WO/2017/184746A1
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that modulate (e.g., agonizes or partially agonizes) NLRP3 tha...  
WO/2017/184775A1
Described herein, inter alia, are compositions of ErbB modulators and methods of using the same.  
WO/2017/181117A1
Described herein are compounds that inhibit ALK2 and its mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.  
WO/2017/178845A1
The present invention relates to compounds of formula I that function as inhibitors of RET (rearranged during transfection) kinase enzyme activity: wherein HET, X1, X2, X3, X4, integer a and R3 are each as defined herein. The present inv...  
WO/2017/176477A1
A composite oligomeric material includes one or more repeating backbone units; one or more polarizable units incorporated into or connected to one or more of the one or more repeating backbone units; and one or more resistive tails conne...  
WO/2017/172507A1
The instant invention provides compounds of formula (I) which are PI3K-delta inhibitors, and as such are useful for the treatment of PI3K-delta-mediated diseases such as inflamation, asthma, COPD and cancer.  
WO/2017/161344A1
Disclosed herein, inter alia, are compositions and methods for treating parasitic diseases.  
WO/2017/159484A1
[Problem] To provide an agent for inhibiting aggregation of tau and/or amyloid β. [Solution] A compound represented by formula (I) or a salt thereof. This compound is used in therapy, diagnosis, and symptom alleviation and in prevention...  
WO/2017/158388A1
The invention relates to novel compounds of formula I which are inhibitors of deubiquitylating enzymes (DUBs) and/or desumoylating enzymes. In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase 7 or ubi...  
WO/2017/159192A1
The present invention relates to: a photoelectric conversion element which has high photoelectric conversion efficiency and low dark current at the same time, while exhibiting high durability; and an optical sensor. A photoelectric conve...  
WO/2017/158616A1
This invention relates to carbapenem compounds, their stereoisomers, pharmaceutically acceptable salts or N-oxides thereof, which may be useful for the treatment of bacterial infections, particularly drug-resistant bacterial infections, ...  
WO/2017/153186A1
The present invention relates novel substituted nucleoside analogues of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invent...  
WO/2017/155103A1
Provided is a novel pest control agent, particularly a pesticide or a miticide. A condensed heterocyclic compound represented by formula (1), a salt of the compound, or an N-oxide of the compound or the salt. [Q represents a structure re...  
WO/2017/152972A1
The present invention is directed to crystalline vinorelbine monotartrate and its use for the prevention and treatment of cancer, particularly non-small cell lung cancer or breast cancer. The present invention also relates to a correspon...  
WO/2017/150474A1
In the present invention, a composition comprising two types of thienothiophene compounds selected from the group consisting of the compounds indicated by formulas (1) to (4) (in formulas (1) to (4), either one of R1 and R2 represents an...  

Matches 1 - 50 out of 9,169